Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Sep 22, 2011

Premium

Silence Therapeutics has named COO Thomas Christely as its new CEO.

He replaces Philip Haworth, who left the company as part of the UK-based company's previously announced reorganization into a wholly European RNAi drugs shop. Haworth was based in California.

Christely served as CFO, and later CEO, of Atugen, an RNAi company that was later acquired by Silence. Before that, he was senior vice president and CFO of OXO Chemie, a Swiss pharmaceutical firm.

Silence also announced that it has appointed Tony Sedgwick as its chief business officer.

He was most recently CEO of biotech firm Novacta. Before that, he served as the CEO of Cambridge Biotechnology and Daniolabs.

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.